A Series Of Novel Triazole Derivatives And Their Impact On Diabetes Management

Abstract

Diabetes mellitus represents a group of chronic metabolic disorders characterized by persistent hyperglycemia due to defects in insulin secretion, action, or both. If left unmanaged, chronic hyperglycemia can lead to severe complications, including cardiovascular diseases, nephropathy, and neuropathy. Current therapeutic approaches focus on lowering blood glucose levels, often employing α-glucosidase and α-amylase inhibitors to control postprandial glucose absorption.

In recent years, considerable attention has been directed toward the development of novel nitrogen-containing heterocyclic compounds, particularly triazoles, as promising α-glucosidase inhibitors. Notably, quinazolinone-1,2,3-triazole hybrids and triazine-triazole derivatives have demonstrated significantly lower IC50 values than the standard drug acarbose, highlighting their potential as effective antidiabetic agents. These findings underscore the importance of ongoing efforts to design and optimize new inhibitors and to explore their structure-activity relationships, aiming to improve therapeutic options for diabetes management.